Androgen receptor degrader
Androgen receptor degrader (ARD) is a type of drug that is designed to target and degrade the androgen receptor (AR), a type of protein that plays a crucial role in the development and progression of prostate cancer. ARDs are a relatively new class of drugs and represent a promising approach to the treatment of prostate cancer.
Mechanism of Action[edit | edit source]
ARDs work by binding to the androgen receptor and inducing its degradation. This is achieved through the recruitment of E3 ubiquitin ligases, which tag the AR for degradation by the proteasome, a cellular machine that breaks down proteins. By degrading the AR, ARDs can effectively reduce the levels of this protein in cancer cells, thereby inhibiting their growth and proliferation.
Development and Clinical Use[edit | edit source]
The development of ARDs has been driven by the need for more effective treatments for prostate cancer, particularly in cases where the disease has become resistant to traditional androgen deprivation therapy (ADT). While ADT can be effective in the early stages of the disease, many patients eventually develop resistance to this treatment, leading to the progression of the disease.
Several ARDs are currently in clinical development, with some showing promising results in early-phase clinical trials. These drugs have the potential to provide a new treatment option for patients with advanced prostate cancer, particularly those who have developed resistance to ADT.
Future Directions[edit | edit source]
While the development of ARDs represents a significant advance in the treatment of prostate cancer, there is still much to learn about these drugs. Future research will likely focus on understanding the precise mechanisms by which ARDs induce AR degradation, as well as identifying potential resistance mechanisms and strategies to overcome them. In addition, further clinical trials will be needed to fully evaluate the safety and efficacy of these drugs in patients with prostate cancer.
See Also[edit | edit source]
 | This pharmacology-related article is a stub. You can help WikiMD by expanding it. |
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
